Supplementary Table 1 from Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Roderic Espín(Bellvitge University Hospital), Miguel Ángel Pujana(Bellvitge University Hospital), Franc Llorens(Bellvitge University Hospital), Mireya Plass(Institut d'Investigació Biomédica de Bellvitge), Daniela Díaz‐Lucena(Biomedical Research Networking Center on Neurodegenerative Diseases), Joel Moss(National Heart Lung and Blood Institute), Carmen Herranz(Bellvitge University Hospital), Marian J.R. Quanjel(St. Antonius Ziekenhuis), Alexandra Baiges(Bellvitge University Hospital), María Molina‐Molina(Instituto de Salud Carlos III), Piedad Ussetti, Claudia Valenzuela(Hospital Universitario de La Princesa), José Antonio Rodríguez-Portal(Instituto de Salud Carlos III), Francesca Mateo(Institut d'Investigació Biomédica de Bellvitge), Joanne J. van der Vis(St. Antonius Ziekenhuis), Julio Ancochea(Hospital Universitario de La Princesa), Eline Blommaert(Bellvitge University Hospital), Álvaro Casanova(Hospital Universitario del Henares), Anna Villar‐Piqué(Universitätsmedizin Göttingen), Antonio Román(Centro de Investigación Biomédica en Red), Rosalía Laporta(Hospital Universitario Puerta de Hierro Majadahonda), Coline H.M. van Moorsel(Inserm), Berta Sáez(Vall d'Hebron Hospital Universitari)
Cited by 0
Related Papers
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
|New England Journal of Medicine|2011|1.1k
Network modeling links breast cancer susceptibility and centrosome dysfunction
|Nature Genetics|2007|634
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
The NHLBI Lymphangioleiomyomatosis Registry
|American Journal of Respiratory and Critical Care Medicine|2005|479
Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells
|Journal of Clinical Investigation|2012|462